Studies conducted on PBMCs obtained from patients with MS have revealed a decrease in BDNF mRNA expression and simultaneous increases in miR-132 and miR-182-5p values (Fig. 1) [134]. This evidence concerns the gene BDNF and myeloid sarcoma.